fluorenes

Summary

Summary: A family of diphenylenemethane derivatives.

Top Publications

  1. pmc Improved diagnostic testing and malaria treatment practices in Zambia
    Davidson H Hamer
    Center for International Health and Development, Boston University School of Public Health, Boston, Mass 02118, USA
    JAMA 297:2227-31. 2007
  2. pmc Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial
    Quique Bassat
    Barcelona Centre for International Health Research CRESIB, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
    PLoS ONE 4:e7871. 2009
  3. ncbi Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial
    Jacek Skarbinski
    Malaria Branch, US Centers for Disease Control and Prevention, Atlanta, Georgia 30341 3724, USA
    Am J Trop Med Hyg 80:919-26. 2009
  4. pmc In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa
    Christin Sisowath
    Infectious Diseases Unit, Department of Medicine and Karolinska Institutet, Stockholm, Sweden
    J Infect Dis 199:750-7. 2009
  5. ncbi Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children
    Emmanuel Arinaitwe
    Makerere University University of California San Francisco Research Collaboration, University of California, San Francisco 94143, USA
    Clin Infect Dis 49:1629-37. 2009
  6. pmc Malaria case-management following change of policy to universal parasitological diagnosis and targeted artemisinin-based combination therapy in Kenya
    Andrew Nyandigisi
    Division of Malaria Control, Ministry of Public Health and Sanitation, Nairobi, Kenya
    PLoS ONE 6:e24781. 2011
  7. ncbi In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem)
    Christin Sisowath
    Malaria Research Laboratory, Unit of Infectious Diseases, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
    J Infect Dis 191:1014-7. 2005
  8. pmc In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1
    Leah Mwai
    Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, Kilifi, Kenya
    Antimicrob Agents Chemother 53:5069-73. 2009
  9. pmc Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin
    Amar bir Singh Sidhu
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, Bronx, NY 10461, USA
    J Infect Dis 194:528-35. 2006
  10. pmc Malaria drug shortages in Kenya: a major failure to provide access to effective treatment
    Beth B Kangwana
    Malaria Public Health and Epidemiology Group, Kenya Medical Research Institute Wellcome Trust Programme Nairobi, Kenya
    Am J Trop Med Hyg 80:737-8. 2009

Research Grants

Detail Information

Publications277 found, 100 shown here

  1. pmc Improved diagnostic testing and malaria treatment practices in Zambia
    Davidson H Hamer
    Center for International Health and Development, Boston University School of Public Health, Boston, Mass 02118, USA
    JAMA 297:2227-31. 2007
    ....
  2. pmc Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial
    Quique Bassat
    Barcelona Centre for International Health Research CRESIB, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
    PLoS ONE 4:e7871. 2009
    ..Dihydroartemisinin-piperaquine (DHA-PQP) is a promising fixed-dose ACT with limited information on its safety and efficacy in African children...
  3. ncbi Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial
    Jacek Skarbinski
    Malaria Branch, US Centers for Disease Control and Prevention, Atlanta, Georgia 30341 3724, USA
    Am J Trop Med Hyg 80:919-26. 2009
    ..30). RDTs could potentially improve malaria case management, but we urgently need to develop more effective strategies for implementing guidelines before large scale implementation...
  4. pmc In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa
    Christin Sisowath
    Infectious Diseases Unit, Department of Medicine and Karolinska Institutet, Stockholm, Sweden
    J Infect Dis 199:750-7. 2009
    ..Identification of drug-specific parasite determinants that contribute to treatment failures will provide important tools for the detection and surveillance of AL resistance...
  5. ncbi Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children
    Emmanuel Arinaitwe
    Makerere University University of California San Francisco Research Collaboration, University of California, San Francisco 94143, USA
    Clin Infect Dis 49:1629-37. 2009
    ..However, which therapies are optimal is a matter of debate. We aimed to compare the short- and longer-term efficacy of 2 leading therapies in a cohort of young Ugandan children...
  6. pmc Malaria case-management following change of policy to universal parasitological diagnosis and targeted artemisinin-based combination therapy in Kenya
    Andrew Nyandigisi
    Division of Malaria Control, Ministry of Public Health and Sanitation, Nairobi, Kenya
    PLoS ONE 6:e24781. 2011
    ..We evaluated changes in health systems and case-management indicators between the baseline survey undertaken before implementation of the policy and the follow-up survey following the first year of the implementation activities...
  7. ncbi In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem)
    Christin Sisowath
    Malaria Research Laboratory, Unit of Infectious Diseases, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
    J Infect Dis 191:1014-7. 2005
    ..This points to 86N as a potential marker of lumefantrine resistance in vivo, while suggesting that Coartem is not robust enough to avoid selection of resistance-associated mutations in some malarial settings...
  8. pmc In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1
    Leah Mwai
    Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, Kilifi, Kenya
    Antimicrob Agents Chemother 53:5069-73. 2009
    ..Therefore, the use of LM-artemether is likely to lead to the selection of more CQ-susceptible parasites...
  9. pmc Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin
    Amar bir Singh Sidhu
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, Bronx, NY 10461, USA
    J Infect Dis 194:528-35. 2006
    ..These results highlight the importance of pfmdr1 copy number in determining P. falciparum susceptibility to multiple agents currently being used to combat malaria caused by multidrug-resistant parasites...
  10. pmc Malaria drug shortages in Kenya: a major failure to provide access to effective treatment
    Beth B Kangwana
    Malaria Public Health and Epidemiology Group, Kenya Medical Research Institute Wellcome Trust Programme Nairobi, Kenya
    Am J Trop Med Hyg 80:737-8. 2009
    ..The shortage was in large part caused by a delayed procurement process. National ministries of health and the international community must address the current shortcomings facing antimalarial drug supply to the public sector...
  11. pmc Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast
    Steffen Borrmann
    Kenya Medical Research Institute Wellcome Trust Research Programme, Kilifi, Kenya
    PLoS ONE 6:e26005. 2011
    ..The emergence of artemisinin-resistant P. falciparum malaria in South-East Asia highlights the need for continued global surveillance of the efficacy of artemisinin-based combination therapies...
  12. pmc SMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology
    Jim Barrington
    SMS for Life Program Director, Forum 1 P 94, Novartis Campus, CH 4056 Basel, Switzerland
    Malar J 9:298. 2010
    ..Lack of visibility of anti-malarial stock levels at the health facility level is an important contributor to this problem...
  13. ncbi Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi
    Kimberly E Mace
    Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Clin Infect Dis 53:772-9. 2011
    ..Because of concerns about the complex dosing schedule, we assessed patient adherence to AL 2 years after routine implementation...
  14. pmc Changes in health workers' malaria diagnosis and treatment practices in Kenya
    Elizabeth Juma
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, PO Box 43640, 00100 GPO, Nairobi, Kenya
    Malar J 10:1. 2011
    ..Three years after the policy implementation, health workers' adherence to malaria diagnosis and treatment recommendations was evaluated...
  15. pmc Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria
    Joel Tarning
    Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Antimicrob Agents Chemother 53:3837-46. 2009
    ..In conclusion, altered pharmacokinetic properties of lumefantrine contribute to the high rates of failure of artemether-lumefantrine treatment in later pregnancy. Dose optimization is urgently needed...
  16. pmc Quality of malaria case management at outpatient health facilities in Angola
    Alexander K Rowe
    Centers for Disease Control and Prevention, Atlanta, USA
    Malar J 8:275. 2009
    ..Implementation was complicated by a policy that was sometimes ambiguous...
  17. pmc Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial
    Jane Achan
    Makerere University School of Health Sciences, PO Box 7475, Kampala, Uganda
    BMJ 339:b2763. 2009
    ..To compare the effectiveness of oral quinine with that of artemether-lumefantrine in treating uncomplicated malaria in children...
  18. ncbi Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda
    Carole Fogg
    Epicentre, Paris, France
    Am J Trop Med Hyg 71:525-30. 2004
    ..The high adherence to artemether-lumefantrine found in our study suggest that this drug is likely to be very effective in Mbarara provided that patients receive clear dosage explanations...
  19. ncbi Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial
    Patrice Piola
    Epicentre, Paris, France
    Lancet Infect Dis 10:762-9. 2010
    ..We aimed to assess whether artemether-lumefantrine was at least as efficacious as oral quinine for the treatment of uncomplicated falciparum malaria during the second and third trimesters of pregnancy in Mbarara, Uganda...
  20. ncbi Deploying artemether-lumefantrine with rapid testing in Ethiopian communities: impact on malaria morbidity, mortality and healthcare resources
    Hailemariam Lemma
    Tigray Health Bureau, Mekelle, Ethiopia
    Trop Med Int Health 15:241-50. 2010
    ....
  21. pmc Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania
    Abdunoor M Kabanywanyi
    Ifakara Health Institute, P, O, Box 78373, Kiko Avenue, Old Bagamoyo Road, Mikocheni, Dar es Salaam, Tanzania
    Malar J 9:48. 2010
    ..Controlled clinical trials have shown that a six-dose regimen of artemether-lumefantrine (AL) therapy for uncomplicated Plasmodium falciparum malaria results in cure rates >95% with good tolerability...
  22. pmc Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town Faculty of Health Sciences, Anzio Road, Observatory, 7925, South Africa
    Malar J 8:S8. 2009
    ..Artemisinin-based combination therapy has made a substantial contribution to reducing the burden of malaria in sub-Saharan Africa...
  23. pmc Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia
    Pharath Lim
    Institut Pasteur in Cambodia, Phnom Penh, Cambodia
    Malar J 8:11. 2009
    ....
  24. ncbi A trial of combination antimalarial therapies in children from Papua New Guinea
    Harin A Karunajeewa
    School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia
    N Engl J Med 359:2545-57. 2008
    ..Malaria control is difficult where there is intense year-round transmission of multiple plasmodium species, such as in Papua New Guinea...
  25. pmc Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda
    Joel Tarning
    Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
    Malar J 11:293. 2012
    ..The objective of this study was to evaluate the population pharmacokinetic properties of artemether and its active metabolite dihydroartemisinin in pregnant women with uncomplicated P. falciparum malaria in Uganda...
  26. pmc Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance
    Maria Isabel Veiga
    Malaria Research Lab, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    PLoS ONE 6:e20212. 2011
    ..Our work unveils new candidate markers of P. falciparum multidrug resistance in vitro, while contributing to the understanding of subjacent genetic complexity, essential for future evidence-based drug policy decisions...
  27. pmc Community case management of fever due to malaria and pneumonia in children under five in Zambia: a cluster randomized controlled trial
    Kojo Yeboah-Antwi
    Center for Global Health and Development, Boston University School of Public Health, Boston, Massachusetts, United States of America
    PLoS Med 7:e1000340. 2010
    ..This study was designed to assess the effectiveness and feasibility of using CHWs to manage nonsevere pneumonia and uncomplicated malaria with the aid of rapid diagnostic tests (RDTs)...
  28. pmc Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts, Kenya
    Harriet Lawford
    The MENTOR Initiative, La Prade, 11150, Villasavary, France
    Malar J 10:281. 2011
    ..This study reports adherence to a specific ACT, artemether-lumefantrine (AL), under conditions of routine clinical practice in Kenya...
  29. pmc Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria
    Sam Salman
    School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia
    Antimicrob Agents Chemother 55:5306-13. 2011
    ....
  30. pmc Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients
    F Ezzet
    Novartis Pharma AG, Basel, Switzerland
    Br J Clin Pharmacol 46:553-61. 1998
    ..While the 4 x 4 dose regimen is very effective in most endemic areas, the poorer absorption (2.5 fold lower than in China) and the more resistant parasites in Thailand require higher doses of this drug...
  31. pmc Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine
    Nahla B Gadalla
    Department of Epidemiology, Tropical Medicine Research Institute, National Centre for Research, Khartoum, Sudan
    Antimicrob Agents Chemother 55:5408-11. 2011
    ..One individual carried parasites with a novel pfmdr1 polymorphism (F1044L). pfmdr1 gene amplification in parasites prior to treatment occurred in three individuals who had recurrent infection during follow-up...
  32. ncbi The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa
    Christin Sisowath
    Malaria Research Unit, Division of Infectious Diseases, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Trop Med Int Health 12:736-42. 2007
    ..e. pfmdr1 gene amplification, pfmdr1 Y184F, S1034C, N1042D, D1246Y, pfcrt S163R and PfATP6 S769N...
  33. ncbi Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial
    Billy E Ngasala
    Malaria Research, Infectious Diseases Unit, Department of Medicine Solna, Karolinska University Hospital, Stockholm, Sweden
    Clin Infect Dis 52:873-82. 2011
    ....
  34. pmc Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study
    Billy E Ngasala
    Malaria Research, Infectious Diseases Unit, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Malar J 10:64. 2011
    ....
  35. pmc Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria
    G S Humphreys
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom
    Antimicrob Agents Chemother 51:991-7. 2007
    ..25; 95% confidence interval, 4.17 to 1441; P, <0.001). We conclude that AL and AQ exert opposite within-host selective effects on the Pfmdr1 gene of P. falciparum...
  36. pmc The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial
    Beth P Kangwana
    Malaria Public Health and Epidemiology Group, Kenya Medical Research Institute Wellcome Trust Research Programme, Kenya
    PLoS Med 8:e1000437. 2011
    ..This study in western Kenya aimed to evaluate the impact of providing subsidized artemether-lumefantrine (AL) through retail providers on the coverage of prompt, effective antimalarial treatment for febrile children aged 3-59 months...
  37. pmc A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya
    Petra F Mens
    Koninklijk Instituut voor de Tropen KIT Royal Tropical Institute, KIT Biomedical Research, Amsterdam, The Netherlands
    Malar J 7:237. 2008
    ....
  38. pmc Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial
    Jean Louis A Ndiaye
    Department of Medical Parasitology, Medical Faculty, Universite Cheikh Anta Diop, Dakar, Senegal
    Malar J 10:237. 2011
    ....
  39. ncbi Increased prevalence of the Plasmodium falciparum Pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine
    Jean Bernard Lekana-Douki
    Unité de Parasitologie Médicale UPARAM, Centre International de Recherches Medicales de Franceville CIRMF, B P 769 Franceville, Gabon
    Infect Genet Evol 11:512-7. 2011
    ....
  40. pmc Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic
    Christian Dokomajilar
    Department of Medicine, University of California San Francisco, San Francisco General Hospital, Box 0811, San Francisco, CA 94143, USA
    Antimicrob Agents Chemother 50:1893-5. 2006
    ..All samples had a single pfmdr1 copy. Treatment with artemether-lumefantrine selects for polymorphisms that may alter antimalarial drug response...
  41. ncbi Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria
    M A van Agtmael
    Department of Clinical Pharmacology and Pharmacotherapy, Academic Medical Center, Amsterdam, The Netherlands
    Int J Antimicrob Agents 12:151-8. 1999
    ..We suggest that auto-induction of gut mucosa enzymes and/or liver enzymes causes a time-dependent increase in first-pass metabolisation of artemether...
  42. pmc In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia
    Jimee Hwang
    U S Centers for Disease Control and Prevention, Atlanta, GA, USA
    Malar J 10:209. 2011
    ..In Ethiopia, artemether-lumefantrine (AL) has been the first-line treatment for uncomplicated P. falciparum malaria since 2004...
  43. pmc Evaluation of recurrent parasitemia after artemether-lumefantrine treatment for uncomplicated malaria in children in western Kenya
    Joseph V Woodring
    Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
    Am J Trop Med Hyg 83:458-64. 2010
    ..This underscores patient counseling on completing all treatment doses for optimal protection from RP...
  44. ncbi No hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria
    Matthew B B McCall
    Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, 6500 HB, Nijmegen, The Netherlands
    Trans R Soc Trop Med Hyg 100:1098-104. 2006
    ..Our results support the continued implementation of artemisinin derivatives in the fight against drug-resistant malaria...
  45. ncbi Artemisinin-based combinations
    Elizabeth A Ashley
    Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand
    Curr Opin Infect Dis 18:531-6. 2005
    ..Artemisinin-based combination treatments have been the mainstay of treatment for falciparum malaria in Southeast Asia for more than 10 years and are now increasingly recommended as first-line treatment throughout the rest of the world...
  46. ncbi The effects of a pre-season treatment with effective antimalarials on subsequent malaria morbidity in under five-year-old children living in high and seasonal malaria transmission area of Burkina Faso
    Alphonse Ouedraogo
    Centre National de Recherche et de Formation sur le Paludisme, Ministere de la Sante, Ouagadougou, Burkina Faso Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso
    Trop Med Int Health 15:1315-21. 2010
    ..To evaluate the effects of pre-season treatment with single dose of sulfadoxine-pyrimethamine (SP) or artemether-lumefantrine (AL) on subsequent malaria morbidity in under-fives...
  47. ncbi Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast
    Babacar Faye
    Service de Parasitologie Mycologie Médicale, Universite Cheikh Anta Diop, Dakar Fann, Senegal
    Trop Med Int Health 15:608-13. 2010
    ....
  48. ncbi Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria
    Elizabeth A Ashley
    Shoklo Malaria Research Unit, Mae Sot, Thailand
    Trop Med Int Health 12:201-8. 2007
    ..If the fixed antimalarial drug combination artemether-lumefantrine (AL) could be given once daily, this should improve adherence and thus effectiveness and lower the risk of selecting for resistance...
  49. pmc Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania
    Eva Maria Staehli Hodel
    Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland
    Antimicrob Agents Chemother 57:950-8. 2013
    ....
  50. pmc Unusual sequence effects on nucleotide excision repair of arylamine lesions: DNA bending/distortion as a primary recognition factor
    Vipin Jain
    Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA
    Nucleic Acids Res 41:869-80. 2013
    ..This work represents a novel 3'-next flanking sequence effect as a unique NER factor for bulky arylamine lesions in E. coli...
  51. pmc Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania
    Erasmus Kamugisha
    Weill Bugando University College of Health Sciences, Mwanza, Tanzania
    Malar J 11:58. 2012
    ....
  52. pmc Adherence to a six-dose regimen of artemether-lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region, Ethiopia
    Hailemariam Lemma
    Tigray Health Bureau, Mekelle, Ethiopia
    Malar J 10:349. 2011
    ..The aim of this study was to measure patient adherence levels to the six-dose AL regimen for the treatment of uncomplicated P. falciparum malaria and to identify its determinant factors in rural areas of the Tigray region, Ethiopia..
  53. pmc Influence of flanking sequence context on the conformational flexibility of aminofluorene-modified dG adduct in dA mismatch DNA duplexes
    Nidhi Jain
    Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA
    Nucleic Acids Res 37:1628-37. 2009
    ....
  54. pmc Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria
    Anja M Carlsson
    Infectious Diseases Unit, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Retzius väg 10, S 171 77 Stockholm, Sweden
    Malar J 10:380. 2011
    ..This study aimed to explore Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment with artemisinin-based combination therapy in children with clinical malaria in a high transmission area in Africa...
  55. pmc Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine
    Shabana Ali
    Department of Pharmacology and Therapeutics, Army Medical College, National University of Sciences and Technology NUST, Islamabad, Pakistan
    Malar J 9:275. 2010
    ..The aim of this study was to evaluate the pharmacokinetics of artemether and its active metabolite, dihydroartemisinin, in healthy Pakistani volunteers...
  56. pmc Implementation of Home based management of malaria in children reduces the work load for peripheral health facilities in a rural district of Burkina Faso
    Alfred B Tiono
    Centre National de Recherche et de Formation sur Paludisme, Ministère de Santé, Ouagadougou, Burkina Faso, West Africa
    Malar J 7:201. 2008
    ..However, the potential fall-out of this community-based strategy on the work burden at the peripheral health facilities level has never been investigated...
  57. ncbi Probing the conformational heterogeneity of the acetylaminofluorene-modified 2'-deoxyguanosine and DNA by 19F NMR spectroscopy
    B P Cho
    Department of Biomedical Sciences, College of Pharmacy, University of Rhode Island, Kingston 02881, USA
    Biochemistry 38:7572-83. 1999
    ..et al. (1997) J. Am. Chem. Soc. 119, 5384-5389]. The exclusive stacked nature of the AAF adducts may provide insight into why AAF adducts are more mutagenic and prone to repair than the nonacetylated AF adducts...
  58. pmc The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria
    Quique Bassat
    Barcelona Centre for International Health Research CRESIB, Hospital Clínic Universitat de Barcelona, Barcelona, Spain
    PLoS Negl Trop Dis 5:e1325. 2011
    ..vivax, and in co-endemic areas where AL is already used routinely against P. falciparum and parasitological differentiation is not routinely performed or only clinical diagnosis is used...
  59. pmc A pharmacy too far? Equity and spatial distribution of outcomes in the delivery of subsidized artemisinin-based combination therapies through private drug shops
    Justin M Cohen
    Clinton Health Access Initiative, 383 Dorchester Ave, Boston MA, 02127, USA
    BMC Health Serv Res 10:S6. 2010
    ..The Government of Tanzania and the Clinton Foundation piloted this subsidized distribution model in two Tanzanian districts to examine concerns about whether the intervention will successfully reach poor, rural communities...
  60. pmc Site-specific incorporation of N-(deoxyguanosin-8-yl)-2-acetylaminofluorene (dG-AAF) into oligonucleotides using modified 'ultra-mild' DNA synthesis
    Ludovic C J Gillet
    Institute for Molecular Cancer Research, University of Zürich August Forel Strasse 7, 8008 Zurich, Switzerland
    Nucleic Acids Res 33:1961-9. 2005
    ..Our synthetic approach should facilitate comprehensive studies of the mechanisms of repair and mutagenesis induced by dG-AAF adducts in DNA and should be of general use for the incorporation of base-labile functionalities into DNA...
  61. pmc Malaria case-management under artemether-lumefantrine treatment policy in Uganda
    Dejan Zurovac
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, Nairobi, Kenya
    Malar J 7:181. 2008
    ..Here the quality of AL case-management is reported from Uganda; approximately one year after AL replaced combination of chloroquine and sulphadoxine-pyrimethamine (CQ+SP) as recommended first line treatment for uncomplicated malaria...
  62. pmc Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria
    Zul Premji
    Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
    PLoS ONE 4:e6682. 2009
    ....
  63. pmc Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi
    David J Bell
    Tropical and Infectious Diseases Unit, Royal Liverpool University Hospital, Liverpool L7 8XP, UK
    Malar J 8:204. 2009
    ..The aim of this study was to investigate the impact of poor adherence on the effectiveness of AL and CPD...
  64. pmc Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children
    Shereen Katrak
    Oregon Health and Science University, Portland, USA
    Malar J 8:272. 2009
    ..However, there is limited data on the safety and tolerability of these drugs, especially in young children and patients co-infected with HIV...
  65. pmc Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria
    C T Happi
    Malaria Research Laboratories, IMRAT, College of Medicine, University of Ibadan, Ibadan, Nigeria
    Antimicrob Agents Chemother 53:888-95. 2009
    ..Pfmdr1 polymorphisms may result in reduction in the therapeutic efficacy of this newly adopted combination treatment for uncomplicated falciparum malaria in Saharan countries of Africa...
  66. pmc Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria?
    Bernhards Ogutu
    Walter Reed Project Centre for Clinical Research Kenya Medical Research Institute, Nairobi, Kenya
    Malar J 9:30. 2010
    ..The potential of this intervention was considered by key scientists in the field at an Advisory Board meeting held in Basel, in April 2009. This article summarizes the discussions that took place among the participants...
  67. pmc Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa
    William Yavo
    Department of Parasitology and Mycology, Faculty of Pharmaceutical and Biological Sciences, Abidjan, Cote d Ivoire
    Malar J 10:198. 2011
    ....
  68. pmc Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania
    Oliver J Sabot
    Malaria Control Team, Clinton Foundation HIV AIDS Initiative, Boston, Massachusetts, USA
    PLoS ONE 4:e6857. 2009
    ..To overcome this challenge, a global ACT subsidy has been proposed. We tested this proposal through a pilot program in rural Tanzania...
  69. ncbi Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial
    Jean François Faucher
    Institut de recherche pour le developpement IRD, Mother and Child Health in the Tropics Research Unit, Cotonou, Benin
    J Infect Dis 200:57-65. 2009
    ..We compared sulfadoxine-pyrimethamine (SP) with unsupervised artemether-lumefantrine (AL) and unsupervised amodiaquine-artesunate (ASAQ) fixed-dose formulation for the treatment of uncomplicated malaria in children in Benin...
  70. ncbi Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria
    Ric N Price
    Centre for Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom
    Clin Infect Dis 42:1570-7. 2006
    ..Our study examined the relative contributions of host, pharmacokinetic, and parasitological factors in determining the therapeutic response to artemether-lumefantrine (AL)...
  71. ncbi Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial
    Antoinette K Tshefu
    Ecole de Santé Publique, Faculte de Medecine, Universite de Kinshasa, Kinshasa, Democratic Republic of the Congo
    Lancet 375:1457-67. 2010
    ..We compared the efficacy and safety of pyronaridine-artesunate with that of artemether-lumefantrine for treatment of uncomplicated P falciparum malaria...
  72. pmc Improvements in access to malaria treatment in Tanzania after switch to artemisinin combination therapy and the introduction of accredited drug dispensing outlets - a provider perspective
    Sandra Alba
    Dept Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Malar J 9:164. 2010
    ..Subsidized ALu was made available in both health facilities and ADDOs. The effect of these interventions on access to malaria treatment was studied in rural Tanzania...
  73. pmc Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme
    Nathan Smith
    Duke Global Health Institute, Trent Hall, Durham, North Carolina, USA
    Malar J 10:316. 2011
    ..The goal of this strategy is to make ACT as affordable as ineffective alternatives. The programme, called the Affordable Medicines Facility - malaria was rolled out in Kenya in August 2010...
  74. pmc Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria
    Darren Creek
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA
    Am J Trop Med Hyg 83:873-5. 2010
    ..27, P = 0.02). Our findings indicate that AL may be better tolerated than DP among young breastfeeding children treated for uncomplicated malaria...
  75. pmc Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria
    Abdoulaye A Djimde
    Malaria Research and Training Center, University of Bamako, Bamako, Mali
    Antimicrob Agents Chemother 55:3994-9. 2011
    ..The results suggest that the dispersible tablet provides adequate systemic exposure to artemether, DHA, and lumefantrine in African children with uncomplicated P. falciparum malaria...
  76. pmc Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania
    Sofia Friberg Hietala
    Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden
    Antimicrob Agents Chemother 54:4780-8. 2010
    ..However, the poor precision in some parameters illustrates the need for further data to support and refine this model...
  77. pmc Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial
    Emmanuelle Espié
    Division of Malaria and Parasitic Diseases, National Institute of Health, Korea Centers for Disease Control and Prevention, Cheongwon gun 363 951, Republic of Korea
    Malar J 11:174. 2012
    ..In order to compare the efficacy of the fixed-dose formulation ASAQ versus artemether-lumefantrine (AL), a randomized, non-inferiority open-label trial was conducted in Katanga...
  78. pmc Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms
    Maja Malmberg
    Malaria Research, Infectious Disease Unit, Department of Medicine Solna, Stockholm, Sweden
    J Infect Dis 207:842-7. 2013
    ..The aim of this study was to investigate the extent to which parasites with different genetic characteristics are able to withstand individual drug blood concentrations...
  79. pmc No evidence for spread of Plasmodium falciparum artemisinin resistance to Savannakhet Province, Southern Laos
    Mayfong Mayxay
    Wellcome Trust Mahosot Hospital Oxford University Tropical Medicine Research Collaboration, Mahosot Hospital, Vientiane, Laos
    Am J Trop Med Hyg 86:403-8. 2012
    ..Serious adverse events did not develop during or after treatment in any patients. In conclusion, no evidence of P. falciparum in vivo resistance to artesunate was found in southern Laos...
  80. pmc Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia
    Christine Manyando
    Tropical Diseases Research Centre, Ndola, Zambia
    Malar J 9:249. 2010
    ..Safety data regarding exposure to artemisinin-based combination therapy in pregnancy are limited. This prospective cohort study conducted in Zambia evaluated the safety of artemether-lumefantrine (AL) in pregnant women with malaria...
  81. pmc Early variations in plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance
    Obaro S Michael
    Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria
    Malar J 9:335. 2010
    ..The study protocol was designed to evaluate more closely the early effects and the standard measures of efficacies of these two regimens...
  82. pmc Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients
    T Kredo
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Antimicrob Agents Chemother 55:5616-23. 2011
    ..The mechanism of the lumefantrine interaction remains to be elucidated. Studies investigating the interaction of nevirapine and artemether-lumefantrine in HIV-infected patients with malaria are urgently needed...
  83. ncbi Mutagenic events in Escherichia coli and mammalian cells generated in response to acetylaminofluorene-derived DNA adducts positioned in the Nar I restriction enzyme site
    Xingzhi Tan
    Laboratory of Chemical Biology, Department of Pharmacological Sciences, State University of New York at Stony Brook, Stony Brook, New York 11794 8651, USA
    Biochemistry 41:14255-62. 2002
    ..3-21%, the higher value at G(2). We conclude from this study that the mutation potential of dG-AAF and dG-AF depends on the structure of the adduct, the sequence context of the lesion, and the host cell used for the experiment...
  84. pmc Rapid selection of Plasmodium falciparum chloroquine resistance transporter gene and multidrug resistance gene-1 haplotypes associated with past chloroquine and present artemether-lumefantrine use in Inhambane District, southern Mozambique
    Thomas T Thomsen
    Section for Functional Genomics, Department of Biology, University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen N, Denmark
    Am J Trop Med Hyg 88:536-41. 2013
    ..In the absence of a clear AL-resistance marker and the (almost) continent-wide use of AL in sub-Saharan Africa, and when considering CQ reintroduction, continued monitoring of these markers is needed...
  85. pmc Feasibility and acceptability of artemisinin-based combination therapy for the home management of malaria in four African sites
    IkeOluwapo O Ajayi
    Malaria Research Laboratories, Institute of Medical Research and Training, College of Medicine, University of Ibadan, Nigeria
    Malar J 7:6. 2008
    ..The feasibility and acceptability of incorporating ACT in HMM needs to be evaluated...
  86. pmc Patterns of anti-malarial drug treatment among pregnant women in Uganda
    Laura R Sangaré
    Department of Global Health, University of Washington, Seattle, WA, USA
    Malar J 10:152. 2011
    ..The study objective was to determine the degree to which presumed episodes of uncomplicated symptomatic malaria in pregnancy were treated with a recommended anti-malarial regimen in a region of Uganda...
  87. pmc Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda
    Frederick N Baliraine
    Department of Medicine, University of California, San Francisco, CA 94143 0811, USA
    J Infect Dis 204:1120-4. 2011
    ..Thus, parasites selected for decreased drug sensitivity can appear long after predicted exposure to antimalarial drugs. Continued surveillance of the clinical efficacy and in vitro activity of new combination therapies is warranted...
  88. ncbi Adherence to artemether/lumefantrine treatment in children under real-life situations in rural Tanzania
    Daudi O Simba
    Department of Community Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
    Trans R Soc Trop Med Hyg 106:3-9. 2012
    ....
  89. pmc Conformational and thermodynamic properties modulate the nucleotide excision repair of 2-aminofluorene and 2-acetylaminofluorene dG adducts in the NarI sequence
    Vipin Jain
    Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA
    Nucleic Acids Res 40:3939-51. 2012
    ..The present results provide valuable conformational insight into the sequence-dependent UvrABC incisions of the bulky aminofluorene DNA adducts...
  90. pmc Association between the pfmdr1 gene and in vitro artemether and lumefantrine sensitivity in Thai isolates of Plasmodium falciparum
    Mathirut Mungthin
    Department of Parasitology, Phramongkutklao College of Medicine, Bangkok, Thailand
    Am J Trop Med Hyg 83:1005-9. 2010
    ..Separate analysis also indicated that parasites from different geographical areas were influenced by different genetic markers...
  91. pmc Overuse of artemisinin-combination therapy in Mto wa Mbu (river of mosquitoes), an area misinterpreted as high endemic for malaria
    Charles Mwanziva
    Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Malar J 7:232. 2008
    ..This study describes diagnostic and treatment practices in Mto wa Mbu, an area that used to be hyperendemic for malaria, but where no recent assessments of transmission intensity have been conducted...
  92. pmc Community response to artemisinin-based combination therapy for childhood malaria: a case study from Dar es Salaam, Tanzania
    Vinay R Kamat
    Department of Anthropology, University of British Columbia, Vancouver, Canada
    Malar J 9:61. 2010
    ..The paper specifically examines the perceived efficacy of ALu as articulated by the mothers of young children diagnosed with malaria and prescribed ALu...
  93. pmc Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria
    F Ezzet
    Novartis Pharma AG, Basel, Switzerland
    Antimicrob Agents Chemother 44:697-704. 2000
    ..The high cure rates with the two six-dose regimens resulted from increased AUC and increased time at which lumefantrine concentrations were above the in vivo MIC...
  94. pmc Treatment with coartem (artemether-lumefantrine) in Papua New Guinea
    Sonja Schoepflin
    Swiss Tropical Institute, Basel, Switzerland
    Am J Trop Med Hyg 82:529-34. 2010
    ..In contrast to the situation in classic drug trials with ideal treatment conditions, our field survey highlights potential problems with unsupervised usage of Coartem in routine clinical practice and under program conditions...
  95. pmc Probing the sequence effects on NarI-induced -2 frameshift mutagenesis by dynamic 19F NMR, UV, and CD spectroscopy
    Nidhi Jain
    Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island 02881, USA
    Biochemistry 46:13310-21. 2007
    ..We also provide evidence for AF/FAF conformational compatibility in the NarI sequences...
  96. ncbi The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria
    Rose McGready
    Shoklo Malaria Research Unit, P O Box 46, Mae Sot, Tak, Thailand
    Eur J Clin Pharmacol 62:1021-31. 2006
    ..To determine the pharmacokinetic properties of artemether and lumefantrine (AL) in pregnant women with recrudescent uncomplicated multi-drug resistant falciparum malaria...
  97. pmc Health facility and health worker readiness to deliver new national treatment policy for malaria in Kenya
    J Njogu
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, P O Box 43640 00100, Nairobi, Kenya
    East Afr Med J 85:213-21. 2008
    ..To evaluate health facility and health worker readiness to deliver new artemether-lumefantrine (AL) treatment policy for uncomplicated malaria in Kenya...
  98. ncbi [Efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Hainan, China]
    Shan Qing Wang
    Hainan Provincial Center for Disease Control and Prevention, Haikou 570203, China
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 26:50-2. 2008
    ....
  99. pmc Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal
    Babacar Faye
    Laboratoire de Parasitologie Mycologie, Faculte de Medecine, Pharmacie et Odontologie, Universite Cheikh Anta Diop, Dakar, Senegal
    Malar J 6:80. 2007
    ....
  100. pmc Translation of artemether-lumefantrine treatment policy into paediatric clinical practice: an early experience from Kenya
    D Zurovac
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, Nairobi, Kenya
    Trop Med Int Health 13:99-107. 2008
    ..To describe the quality of outpatient paediatric malaria case-management approximately 4-6 months after artemether-lumefantrine (AL) replaced sulfadoxine-pyrimethamine (SP) as the nationally recommended first-line therapy in Kenya...
  101. pmc Why don't health workers prescribe ACT? A qualitative study of factors affecting the prescription of artemether-lumefantrine
    Beatrice Wasunna
    Eastern and Southern Africa Centre of International Parasite Control ESACIPAC KEMRI, P O Box 54840 00200, Nairobi, Kenya
    Malar J 7:29. 2008
    ..New national guidelines on the diagnosis, treatment and prevention were developed and disseminated to health workers together with in-service training...

Research Grants32

  1. MAMMARY CARCINOGENESIS BY N-SUBSTITUTED ARYL COMPOUNDS
    Danuta Malejka Giganti; Fiscal Year: 2000
    ..3) To determine the capacity of rat mammary microsomes to bioactivate fluorenes by C-9 hydroxylation, to determine the mutagenicity of C9-oxidized fluorenes in Salmonella typhimurium and to ..
  2. Two-Photon Fluorescence Probe Development for in Vivo Spatial and Temporal Angiog
    KEVIN BELFIELD; Fiscal Year: 2008
    ..Such a breakthrough will afford a better understanding of disease processes and the mechanism of action of drugs and other species in vivo. [unreadable] [unreadable] [unreadable]..
  3. Sequence Effects of Arylamine-DNA Adducts: Repair and Replication
    BONGSUP CHO; Fiscal Year: 2008
    ..Such knowledge will also be of help in the development of sensible prevention and risk assessment strategies. ..
  4. Alkynyliodonium Salts and Derived Diyls in Synthesis
    Ken Feldman; Fiscal Year: 2009
    ..abstract_text> ..
  5. New Methodology for Indole Alkaloid Syntheses
    Ken S Feldman; Fiscal Year: 2010
    ..The use of a new variant of the Pummerer reaction to control both oxidation level and reaction site within the indole nucleus forms the basis of this chemistry. ..
  6. Chemical and Biological Studies on Biaryl Phenolics
    Ken Feldman; Fiscal Year: 2005
    ..The search for selective 20S proteosome inhibitors among the Ntn-type proteases will be advanced by these investigations. ..
  7. Burden of Malaria in Pregnancy in India
    Davidson Hamer; Fiscal Year: 2007
    ..The information generated by the study will also be instrumental in the development of new programs for preventing and mitigating the impact of MIP in India. [unreadable] [unreadable] [unreadable]..
  8. THE ROLE OF SULFATIDES IN ALZHEIMER'S DISEASE
    Xianlin Han; Fiscal Year: 2008
    ..abstract_text> ..
  9. GENETIC ANALYSIS OF BONE STRENGTH IN MICE
    Robert Klein; Fiscal Year: 2009
    ..Discovery of the genes essential for optimal bone quality would offer tremendous insight into a poorly understood, but critically important component of overall bone strength. ..
  10. SYNTHESIS OF ANTICANCER AGENTS
    K C Nicolaou; Fiscal Year: 2010
    ..abstract_text> ..
  11. Small molecule inhibitors of bacterial secretion system
    Vincent Lee; Fiscal Year: 2008
    ..abstract_text> ..
  12. TOTAL SYNTHESIS OF APOPTOLIDIN
    K Nicolaou; Fiscal Year: 2004
    ..The proposed work is expected to have significant impact in the area of cancer chemotherapy and should provide enabling technologies and tools for biology and medicine. ..
  13. Deciphering how glycosylation protects peptides from proteolysis
    Michael Carrasco; Fiscal Year: 2007
    ..Understanding and using how attaching sugars to peptides protects them from digestion would enable the creation of new classes of powerful peptide pharmaceuticals. [unreadable] [unreadable] [unreadable]..
  14. TOTAL SYNTHESIS OF AZADIRACHTIN
    K Nicolaou; Fiscal Year: 2008
    ..The proposed work is expected to impact the general areas of pharmaceutical and agricultural research, and infectious diseases in particular, through discoveries in synthetic organic chemistry and chemical biology. ..
  15. PHYSIOLOGICALLY ACTIVE NATURAL PRODUCTS
    Douglass Taber; Fiscal Year: 2007
    ..In the course of these investigations, new molecular reactivity will be developed that will substantially shorten current routes to polycyclic natural products and drug candidates. ..
  16. TOTAL SYNTHESIS OF NATURAL PRODUCTS
    K Nicolaou; Fiscal Year: 2002
    ..3] sigmatropic rearrangement and a radical based ring closure to form the bicyclic skeleton. ..
  17. Excitatory Amino Acid Release in Ischemia
    HAROLD KIMELBERG; Fiscal Year: 2005
    ..The second half of the project that deals with neuroprotection has direct potential clinical implications, as TAM is known to be well tolerated in humans being widely used for breast cancer treatment. ..
  18. Host genes required for P. aeruginosa pathogenesis
    Vincent Lee; Fiscal Year: 2004
    ..abstract_text> ..
  19. Development of PET radioligands for cerebral cannabinoid receptor (CB1)
    ANDREW HORTI; Fiscal Year: 2008
    ....
  20. Investigating the Molecular Mechanism of Hexose-induced Stress in Lens and Retina
    Peter F Kador; Fiscal Year: 2010
    ..Moreover, these studies should help identify new drug targets for the treatment of these diabetic complications. ..
  21. Roles of CYP1 & 19 in Fundulus Steroids & PAH Metabolism
    Kristine Willett; Fiscal Year: 2009
    ..This research will further define the utility of Fundulus as a model organism for studying PAH-associated toxicities and in the development of human CYP19 or CYP1 B-related therapeutics. ..
  22. Prevention of Breast Cancer-Targeting COX-2 & PPARgamma
    ALAA BADAWI; Fiscal Year: 2003
    ..abstract_text> ..
  23. REACTIVE INTERMEDIATES OF CARCINOGENESIS OF PAHS
    KENNETH LAALI; Fiscal Year: 2004
    ..DNA binding and mammalian cell mutagenicity studies on the substituted and derivatized-PAHs proposed for stable ion work will enhance the available literature data on structure/reactivity relationships. ..
  24. Enabling Technologies for Combinatorial Chemistry
    K Nicolaou; Fiscal Year: 2005
    ..abstract_text> ..
  25. IMMUNE RESPONSES TO P FALCIPARUM IN HIGHLAND KENYA
    Chandy John; Fiscal Year: 2002
    ..falciparum antigens to susceptibility to infection and disease is important in the evaluation of these antigens as malaria vaccine candidates. ..
  26. Carcinogenicity of Estrogens
    DAVID SPINK; Fiscal Year: 2009
    ..These studies may elucidate roles of estrogen in the regulation of Ah responsiveness, CYP1 expression, and carcinogen bioactivation that may lead to novel breast cancer chemoprevention strategies. ..
  27. Multifunctional Antioxidants as Anti-Cataract Agents
    Peter Kador; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  28. Congenital and neonatal malaria in Mali
    Abdoulaye Djimde; Fiscal Year: 2006
    ..research grant ..
  29. Host Polymorphisms and Uncomplicated Malaria
    Sunil Parikh; Fiscal Year: 2008
    ..Parikh will be able to utilize modern molecular epidemiology techniques to investigate human genetic factors underlying susceptibility to malaria and he will be well equipped for a career in academic research. ..
  30. Contribution of ATGL in skeletal muscle to lipid metabolism and insulin action
    ERIN KERSHAW; Fiscal Year: 2008
    ..Evaluating the role of ATGL-mediated fat breakdown in skeletal muscle will provide important insights into the pathophysiology and treatment of obesity, insulin resistance, and related metabolic disorders. [unreadable] [unreadable]..
  31. Study of a New Class of Chiral Nucleophilic Catalysts
    VLADIMIR BIRMAN; Fiscal Year: 2008
    ..unreadable] [unreadable]..